Abbott Laboratories Ownership
| ABT Stock | USD 130.61 1.18 0.90% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 1.7 B | Current Value 1.7 B | Avarage Shares Outstanding 1.7 B | Quarterly Volatility 115.3 M |
Abbott |
Abbott Stock Ownership Analysis
About 79.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.35. Abbott Laboratories recorded earning per share (EPS) of 7.64. The entity last dividend was issued on the 15th of January 2025. The firm had 10000:4798 split on the 2nd of January 2013. Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. Abbott Laboratories operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 113000 people. For more info on Abbott Laboratories please contact Miles White at 224 667 6100 or go to https://www.abbott.com.Besides selling stocks to institutional investors, Abbott Laboratories also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Abbott Laboratories' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Abbott Laboratories' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Abbott Laboratories Quarterly Liabilities And Stockholders Equity |
|
Abbott Laboratories Insider Trades History
Less than 1% of Abbott Laboratories are currently held by insiders. Unlike Abbott Laboratories' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Abbott Laboratories' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Abbott Laboratories' insider trades
Abbott Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Abbott Laboratories is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Abbott Laboratories backward and forwards among themselves. Abbott Laboratories' institutional investor refers to the entity that pools money to purchase Abbott Laboratories' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Legal & General Group Plc | 2024-09-30 | 14.3 M | Polen Capital | 2024-09-30 | 13.9 M | Bank Of New York Mellon Corp | 2024-12-31 | 13.6 M | State Farm Mutual Automobile Ins Co | 2024-09-30 | 13.6 M | Massachusetts Financial Services Company | 2024-09-30 | 13.3 M | Charles Schwab Investment Management Inc | 2024-12-31 | 12.9 M | Ameriprise Financial Inc | 2024-09-30 | 12.1 M | Deutsche Bank Ag | 2024-09-30 | 11.5 M | Bank Of America Corp | 2024-09-30 | 11.4 M | Vanguard Group Inc | 2024-09-30 | 167.9 M | Blackrock Inc | 2024-09-30 | 131 M |
Abbott Laboratories Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abbott Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abbott Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Abbott Laboratories insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Daniel Salvadori over two weeks ago Disposition of 23771 shares by Daniel Salvadori of Abbott Laboratories at 38.4 subject to Rule 16b-3 | ||
Hubert Allen over two weeks ago Disposition of 131360 shares by Hubert Allen of Abbott Laboratories at 38.4 subject to Rule 16b-3 | ||
Louis Morrone over two weeks ago Disposition of 2644 shares by Louis Morrone of Abbott Laboratories at 127. subject to Rule 16b-3 | ||
Mccoy John A. Jr. over three months ago Disposition of tradable shares by Mccoy John A. Jr. of Abbott Laboratories at 113.27 subject to Rule 16b-3 | ||
Robert Alpern over six months ago Acquisition by Robert Alpern of tradable shares of Abbott Laboratories subject to Rule 16b-3 |
Abbott Laboratories' latest congressional trading
Congressional trading in companies like Abbott Laboratories, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Abbott Laboratories by those in governmental positions are based on the same information available to the general public.
| 2025-01-31 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2025-01-30 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2025-01-23 | Representative Thomas H Kean | Acquired Under $15K | Verify | ||
| 2024-12-31 | Senator Markwayne Mullin | Acquired $15K to $50K | Verify | ||
| 2024-12-30 | Senator Markwayne Mullin | Acquired $15K to $50K | Verify | ||
| 2024-12-18 | Representative Michael McCaul | Acquired $15K to $50K | Verify | ||
| 2024-09-18 | Representative Michael McCaul | Acquired $50K to $100K | Verify | ||
| 2024-09-06 | Representative John James | Acquired Under $15K | Verify | ||
| 2024-09-02 | Representative John James | Acquired Under $15K | Verify | ||
| 2024-08-21 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
| 2024-08-19 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
| 2024-08-16 | Representative Kathy Manning | Acquired Under $15K | Verify | ||
| 2024-02-02 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
| 2024-02-01 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
| 2023-11-01 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2023-10-31 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2023-10-20 | Senator Pete Ricketts | Acquired $100K to $250K | Verify | ||
| 2022-08-13 | Representative Dean Phillips | Acquired Under $15K | Verify | ||
| 2022-05-13 | Representative Robert J Wittman | Acquired Under $15K | Verify | ||
| 2022-01-27 | Representative Michael C Burgess | Acquired Under $15K | Verify | ||
| 2019-04-24 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
| 2019-04-23 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
| 2019-04-05 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
| 2018-12-12 | Representative Thomas J Rooney | Acquired $15K to $50K | Verify | ||
| 2018-05-05 | Representative Pete Sessions | Acquired Under $15K | Verify | ||
| 2015-08-03 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
| 2015-08-02 | Senator Shelley Moore Capito | Acquired Under $15K | Verify |
Abbott Laboratories Outstanding Bonds
Abbott Laboratories issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Abbott Laboratories uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Abbott bonds can be classified according to their maturity, which is the date when Abbott Laboratories has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ABBOTT LABS 295 Corp BondUS002824BB55 | View | |
| ABBOTT LABS 6 Corp BondUS002824AV29 | View | |
| ABBOTT LABS 53 Corp BondUS002824AY67 | View | |
| US002824BP42 Corp BondUS002824BP42 | View | |
| US002824BQ25 Corp BondUS002824BQ25 | View | |
| ABBOTT LABS 475 Corp BondUS002824BG43 | View | |
| US002824BF69 Corp BondUS002824BF69 | View | |
| ABBOTT LABS 49 Corp BondUS002824BH26 | View |
Abbott Laboratories Corporate Filings
F4 | 7th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 22nd of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 31st of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 25th of June 2024 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Abbott Stock Analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.